Latar BelakangKanker ginekologi dan infeksi COVID-19 memiliki tingkat insidensi dan mortalitas yang tinggi di Indonesia serta berdampak pada aspek kesehatan, sosial, dan budaya. Kanker ginekologi dan infeksi COVID-19 memicu inflamasi yang dapat mengakibatkan ganguan multi-organ. Pemeriksaan laboratorium dapat digunakan sebagai indikator keparahan untuk menilai inflamasi dan kerusakan organ. Oleh karena itu penelitian ini akan membahas mengenai analisis kakteristik klinis dan hasil laboratorium pasien kanker ginekologi dengan COVID-19.MetodeMetode yang akan digunakan di dalam penelitian ini adalah deskritif dan analitik dengan pendekatan potong lintang retrospektif.HasilTingkat insidensi pasien kanker ginekologi dengan COVID-19 2020-2022 sebesar 154 per 100.000. Kanker serviks (54,3%) menjadi diagnosis terbanyak diikuti dengan kanker ovarium (28,7%), kanker rahim (14,9%), kanker vulva (1,1%), dan kanker vagina (1,1%). Stadium III (37,2%) menjadi yang terbanyak diikuti stadium IV (26,6%), stadium I (20,2%), stadium II (16%). Karakteristik klinis dan hasil laboratorium yang memiliki hubungan signifikan dengan stadium kanker adalah obesitas (OR 0,321; CI 0,125-0,826; P value 0,018), neutrofil absolut tinggi (OR 5,006; Cl 95%, 1,307 – 19,176; P value 0,019), ureum tinggi (OR 3,977; Cl 95%, 1,112 – 14,224; P value 0,034), dan platelet to leucocyte ratio (PLR) tinggi (OR 7,379; 95% CI 2,067-26,466; P value 0,002). Karakteristik klinis dan hasil laboratorium yang memiliki hubungan signifikan dengan derajat keparahan COVID-19 adalah sesak napas (OR 12,364; Cl 95%, 4,148 – 36,848; P value <0.001) dan PLR tinggi (OR 6,787; 95% CI 1,103 - 41,774; P value 0,039).KesimpulanKarakteristik klinis dan hasil laboratorium yang dapat dikaitkan sebagai indikator keparahan berdasarkan stadium kanker ginekologi adalah obesitas, neutrofil absolut tingg, ureum dan PLR tinggi. Karakteristik klinis dan hasil laboratorium yang dapat dikaitkan dengan indikator keparahan berdasarkan derajat keparahan COVID-19 adalah sesak napas dan PLR tinggi.

---

Introduction

Gynecologic cancer and COVID-19 infection have high incidence and mortality rates in Indonesia and impact health, social and cultural aspects. Gynecological cancers and COVID-19 infections trigger inflammation that can lead to multi-organ disorders. Laboratory tests can be used as an indicator of severity to assess inflammation and organ damage. Therefore, this study will discuss the analysis of clinical characteristics and laboratory results of gynecological cancer patients with COVID-19.

Method

The method used in this study is descriptive and analytic with a retrospective cross- sectional approach.

Results

The incidence rate of gynecologic cancer patients with COVID-19 2020-2022 was 154 per 100,000. Cervical cancer (54.3%) was the most common diagnosis followed by ovarian cancer (28.7%), uterine cancer (14.9%), vulvar cancer (1.1%), and vaginal cancer (1.1%). Stage III (37.2%) was the most common followed by stage IV (26.6%), stage I (20.2%), stage II (16%). Clinical characteristics and laboratory results that had a significant association with cancer stage were obesity (OR 0,321; CI 0,125-0,826; P value 0,018), high absolute neutrophils (OR 5.006; 95% CI, 1.307-19.176; P value 0.019), high high ureum level (OR 3.977; 95% CI, 1.112-14.224; P value 0.034), and high PLR (OR 7.379; 95% CI 2.067-26.466; P value 0.002). Clinical characteristics and laboratory results that had a significant association with COVID-19 severity were shortness of breath (OR 12.364; Cl 95%, 4.148 - 36.848; P value <0.001) and high PLR (OR 6.787; 95% CI 1.103 - 41.774; P value 0.039).

Conclusion Clinical characteristics and laboratory results associated with gynecologic cancer stage were obesity, high absolute neutrophils, high ureum level, and high PLR. Clinical characteristics and laboratory results associated with COVID-19 severity were shortness of breath and high PLR.